Performance and Safety of the Cardiac Microcurrent Therapy System (C-MIC-II)

  • End date
    Aug 31, 2024
  • participants needed
  • sponsor
    Berlin Heals GmbH
Updated on 4 April 2023


Patients with idiopathic dilative cardiomyopathy who have systolic left ventricular dysfunction (NYHA III - IV) despite adequate therapy according treatment guidelines of heart failure and who have a baseline left ventricular ejection fraction of ≥25% and ≤35 will receive a C-MIC System and microcurrent therapy after device implantation with optimal medical management. At the end of the study after 6 months, the C-MIC System will be turned off. The control group will receive optimal medical management without device implantation.


Target patients for the C-MIC System are patients with idiopathic dilative cardiomyopathy who have systolic left ventricular dysfunction (NYHA class III - NYHA class IV) despite adequate therapy of heart failure and a left ventricular ejection fraction ranging from 25% to 35% with a history of heart failure of more than 1 year but less than 5 years.

Study objective is to determine the safety and effectiveness of C-MIC therapy in patients with moderate to severe heart failure under optimal medical therapy. Data from a pilot study (C-MIC-I) indicate that an increase of ≥ 8% of the left ventricular ejection fraction can be achieved within a treatment period of 6 month. Hence, study hypothesis is that an increase in LVEF of ≥ 8% can be achieved.

Subjects will be randomized in a 1:1 ratio to receive the C-MIC System in addition to optimal medical management or to receive optimal medical management alone without device. Due to the risks associated with the implantation, a sham (placebo) procedure is not justified.

The primary endpoint will be the change of left ventricular ejection fraction (LVEF) from baseline after 6 months assessed via cardiac ultrasound in %. LVEF measurements will be verified by a core lab at baseline, week 4 (only C-MIC group), month 4 and month 6.

Condition Systolic Left Ventricular Dysfunction
Treatment Standard of Care (SOC), CMIC
Clinical Study IdentifierNCT04662034
SponsorBerlin Heals GmbH
Last Modified on4 April 2023


Yes No Not Sure

Inclusion Criteria

Patients with idiopathic dilative cardiomyopathy who have systolic left ventricular dysfunction despite of adequate therapy of heart failure (NYHA III - IV (ambulatory))
Patients with symptomatic chronic heart failure for more than 1 year and less than 5 years at screening
Patients who have a baseline left ventricular ejection fraction of ≥25% and ≤35% assessed by echocardiography within 30 days prior to study inclusion
Patient who understands the nature of the procedure and on-going device therapy. Patient is informed about their participation in a chronic human study and about the intended treatment period of 6 months which is derived by the fact that according to current knowledge microcurrent treatment exceeding 6 months will not have additional favorable effects which means will not further improve cardiac function. Accordingly, battery life is limited. Furthermore, the patient is informed about the possibility for device explantation, informed regarding possible risks and is able to give written informed consent prior to any procedures and is considered willing and able to adhere to study regimen and to return for all follow-up visits
Patients are receiving guideline conform heart failure therapy
Patients receiving appropriate, stable guideline conform anti-heart failure therapy during the 3 months prior study inclusion (OMM). Stable is defined as no more than a 50% increase or 50% decrease in dose. If the patient is intolerant to full anti-heart failure medication, documented evidence must be available
Patients who are able to perform a 6-minute walk test
Patients must have a body mass index within the range of 20 - 36 kg/m²
Informed consent in writing from patient
Patients with an ICD systems can be included providing patients are not pacemaker dependent and the ICD system uses a single coil electrode the leads can be implanted in such a way that it is ensured, that the metal parts of the coil electrodes do not touch each other

Exclusion Criteria

Patients who have a potentially correctible cause of heart failure, such as valvular heart disease or congenital heart disease
Patients with an indication for a CRT system according to current guidelines
Patients who have been hospitalized for heart failure which required the use of inotropic support within 30 days before enrollment
Patients with systolic blood pressure above 150 mmHg and diastolic blood pressure above 90 mmHg despite optimal antihypertensive medical treatment
Patients with hemoglobin blood level < 12 g/dl in male and < 10 g/dl in female patients
Patients with primary pulmonary hypertension
Patients who have a genetic connective tissue disease (for example Marfan syndrome)
Patients with constrictive pericarditis
Patients with a prosthetic tricuspid valve
Patients in whom access for implantation of the leads cannot be obtained (i.e., known venous occlusion, post radiation therapy)
Patients who have other preexisting epicardial leads
Patients who have undergone prior heart surgery
Patient with other features (i.e., thorax deformity) that in the eyes of the investigator make the straightforward placement of the device seem unlikely
Patients with an ICD system who are pacemaker dependent
Patients with an ICD system with a dual coil electrode
Patients with a CRT system or pacemaker
Patients with a CCM system
Current pregnancy or
Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception (e.g., intrauterine device, oral contraceptives, barrier methods, or other contraception deemed adequate by the investigator) 2 months before and until 1 month after C-MIC therapy
Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 2 months before screening
Breastfeeding/lactating women
Patients whose exercise tolerance is limited by a condition other than heart failure (e.g., chronic obstructive pulmonary disease, peripheral vascular disease, orthopedic or rheumatologic conditions) or who are unable to participate in a 6-minute walk test
Patients on immunosuppressive therapy
Patients with present malignancy
Patients with an active infection considered by the investigator to be unsafe for the patient's participating in the trial
Patients with renal dysfunction (i.e., estimated glomerular filtration rate <45 mL/min / 1,73 m²)
Patients with history or presence of relevant liver diseases or hepatic dysfunction as indicated by abnormal liver function tests at screening and baseline: ALT (SGPT), AST (SGOT), γ-GT, alkaline, phosphatase and serum bilirubin > 2 × upper limit of normal (ULN). Increase of these liver enzymes caused by cardiac disorders in the absence of other possible causes of liver damage are not are not meant by this
Patients with a history of drug or alcohol abuse within the 12 months prior to screening
Patients who, in the opinion of the Principal Investigator, are unlikely to comply with the protocol requirements, instructions and trial related restrictions, e.g., uncooperative attitude, inability to return for follow-up visits, psychological illness, and improbability of completing the trial
Participation in any study of an investigational device or drug within 90 days prior to planned study
Vulnerable Patients (e.g., patients requiring a legal representative, patients kept in detention, any service within the army, and employees of the sponsor or at an investigator site)
Patients who are not able to avoid the following areas (i.e., due to work) such as areas with strong magnetic fields, areas with strong external electrical influences, areas with a warning notice "Access prohibited for pacemaker patients" or similar and areas with high temperatures
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note